Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Analysis: If SpaceX were to merge with Tesla, a $3.4 trillion mega corporation could be born

Analysis: If SpaceX were to merge with Tesla, a $3.4 trillion mega corporation could be born

BlockBeatsBlockBeats2026/06/01 12:55

BlockBeats News, June 1st, according to

Fortune
analysis, if Musk pushes for a SpaceX and Tesla merger, the new company's valuation could reach around $34 trillion, with SpaceX valued at approximately $17.5 trillion and Tesla at about $16.5 trillion. This would become the largest M&A deal in history, nearly three times the size of the current largest deal.


However, the financial rationale of this deal is being questioned. The analysis suggests that SpaceX would need to issue new shares equivalent to about 94% of its current shares to complete the acquisition. Additionally, Tesla's profitability has significantly declined in recent years, with its GAAP net income dropping from $15 billion in 2023 to around $3.9 billion, and its core operating profit, excluding regulatory credits and Bitcoin gains, is only about $2.3 billion.


The report suggests that this move is more like using the market's high valuation expectations for a SpaceX IPO to support Tesla, rather than being a merger driven by traditional financial metrics.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

After Eli Lilly's nearly 300% surge in four years, Wall Street remains bullish: The "hidden pipeline" beyond GLP-1 is underestimated

Eli Lilly’s share price has surged nearly 300% since the approval of its first GLP-1 drug, with its market capitalization surpassing 1 trillion USD, yet Wall Street remains optimistic about its continued growth. Berenberg has upgraded Eli Lilly’s rating to “Buy," believing that Mounjaro and Zepbound will continue to see strong volume, and that the oral GLP-1 drug could further drive demand. Additionally, Eli Lilly continues to expand into areas such as cancer and sleep disorders, and the potential of its non-obesity-related pipelines remains underestimated by the market.

华尔街见闻2026/09/18 13:21

Goldman Sachs: The industrial sector is "even more expensive" than tech stocks; global sector pricing logic is changing

The 12-month forward price-to-earnings ratio of the industrial sector has now surpassed that of the technology sector, indicating that the relative valuations among various sectors in global stock markets are undergoing a shift.

智通财经2026/09/18 13:11